A rare form of immunodeficiency condition: Roifman syndrome

Roifman syndrome is a rare hereditary disease characterized by a defect in the humoral link of immunity, spondyloepiphyseal dysplasia, stunted growth and intellectual development, as well as retinal dystrophy. Roifman syndrome was first described in 1999, and in 2015 pathogenic mutations in the RNU4ATAC gene associated with Roifman syndrome, Taybi–Linder syndrome (TALS), or primary osteodysplastic dwarfism with type 1 microcephaly (MOPD1), and Lowry–Wood syndrome (LWS) were identified. Clinical manifestations of Roifman syndrome include microcephaly, a narrow nasal bridge, growth retardation and immunological disorders leading to frequent respiratory infections and a decrease in quality of life. The prognosis for children with this disease is more favorable compared to other RNU4ATAC-opathies, such as MOPD1. The article describes a clinical case demonstrating a long-term diagnostic path to diagnosis verification and the importance of early diagnosis of rare forms of immunodeficiency conditions in order to improve the quality of life of children. From an early age, the patient had characteristic clinical manifestations in the form of phenotypic features and multiple organ complaints. The child was observed for a long time by specialist doctors with various nosological forms. Despite treatment, no improvement was observed, and complaints increased. Sequencing of the complete exome in 2017 did not allow the diagnosis to be verified. However, during a more extensive genetic examination, sequencing of the complete genome in 5 years, in 2022, Roifman syndrome was confirmed. The appearance of previously undescribed mutations and the expansion of DNA diagnostic methods made it possible to verify the diagnosis and initiate substitution therapy in order to improve the quality of life.

1. Roifman C.M. Antibody deficiency, growth retardation, spondyloepiphyseal dysplasia and retinal dystrophy: a novel syndrome. Clin Genet 1999; 55(2): 103–109. DOI: 10.1034/j.1399–0004.1999.550206.x.

2. Merico D., Roifman M., Braunschweig U., Yuen R.K., Alexandrova R., Bates A. et al. Compound heterozygous mutations in the noncoding RNU4ATAC cause Roifman Syndrome by disrupting minor intron splicing. Nat Commun 2015; 2(6): 8718. DOI: 10.1038/ncomms9718

3. Thomas P.S., Nevin N.C. Congenital familial dwarfism with cephalo-skeletal dysplasia. Ann Radiol (Paris) 1976; 19(1): 187–192

4. Edery P., Marcaillou C., Sahbatou M., Labalme A., Chastang J., Touraine R. et al. Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA. Science 2011; 332(6026): 240–243. DOI: 10.1126/science.1202205

5. He H., Liyanarachchi S., Akagi K., Nagy R., Li J., Dietrich R.C., et al. Mutations in U4atac snRNA, a component of the minor spliceosome, in the developmental disorder MOPD I. Science 2011; 332(6026): 238–240. DOI: 10.1126/science.1200587

6. Lowry R.B., Wood B.J. Syndrome of epiphyseal dysplasia, short stature, microcephaly and nystagmus. Clin Genet 1975; 8(4): 269–274. DOI: 10.1111/j.1399–0004.1975.tb01502.x

7. Duker A., Velasco D., Robertson N., Jackson A., DeFelice M., Bober M.B. RNU4atac-opathy. In: Adam M.P., Feldman J., Mirzaa G.M., Pagon R.A., Wallace S.E., Amemiya A., et al. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. Available from: http://www.ncbi.nlm.nih.gov/books/NBK589232/

8. Pierce M.J., Morse R.P. The neurologic findings in Taybi–Linder syndrome (MOPD I/III): case report and review of the literature. Am J Med Genet A 2012; 158A(3): 606–610. DOI: 10.1002/ajmg.a.33958

9. Sigaudy S., Toutain A., Moncla A., Fredouille C., Bourlière B., Ayme S., et al. Microcephalic osteodysplastic primordial dwarfism Taybi–Linder type: report of four cases and review of the literature. Am J Med Genet 1998; 80(1): 16–24

10. Krøigård A.B., Jackson A.P., Bicknell L.S., Baple E., Brusgaard K., Hansen L.K., et al. Two novel mutations in RNU-4ATAC in two siblings with an atypical mild phenotype of microcephalic osteodysplastic primordial dwarfism type 1. Clin Dysmorphol 2016; 25(2): 68–72. DOI: 10.1097/MCD.0000000000000110

11. Clifford D., Moloney F., Leahy T.R., Murray D.M. Roifman syndrome: a description of further immunological and radiological features. BMJ Case Rep 2022; 15(4): e249109. DOI: 10.1136/bcr-2022–249109

12. Ballios B.G., Mandola A., Tayyib A., Tumber A., Garkaby J., Vong L., et al. Deep phenotypic characterization of the retinal dystrophy in patients with RNU4ATAC-associated Roifman syndrome. Eye (Lond) 2023; 37(18): 3734–3742. DOI: 10.1038/s41433–023–02581–1

13. Fairchild H.R., Fairchild G., Tierney K.M., McCartney D.L., Cross J.J., de Vries P.J. Partial agenesis of the corpus callosum, hippocampal atrophy, and stable intellectual disability associated with Roifman syndrome. Am J Med Genet A 2011; 155A(10): 2560–2565. DOI: 10.1002/ajmg.a.34215

14. Roifman C.M. Primary T-Cell Immunodeficiencies. In: Clinical Immunology [Internet]. Elsevier; 2019 [cited 2024 Nov 7]: 489–508. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780702068966000351

15. Tangye S.G., Al-Herz W., Bousfiha A., Cunningham-Rundles C., Franco J.L., Holland S.M., et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022; 42(7): 1473–1507. DOI: 10.1007/s10875–022–01289–3

16. Gutierrez M., Deng Z., McElwee J., Siegel R.M., Hanson E. U4ATAC Mutation Is Associated with an Immune Dysregulation Syndrome Characterized By Primary Immunodeficiency, Short Stature and Polyglandular Endocrinopathy [abstract]. Arthritis Rheumatol 2016; 68 (suppl 10).

17. Mandel K., Grunebaum E., Benson L. Noncompaction of the myocardium associated with Roifman syndrome. Cardiol Young 2001; 11(2): 240–243. DOI: 10.1017/s1047951101000208

18. Robertson S.P., Rodda C., Bankier A. Hypogonadotrophic hypogonadism in Roifman syndrome. Clin Genet 2000; 57(6): 435–438. DOI: 10.1034/j.1399–0004.2000.570606.x

19. Schejter Y.D., Ovadia A., Alexandrova R., Thiruvahindrapuram B., Pereira S.L., Manson D.E., et al. A homozygous mutation in the stem II domain of RNU4ATAC causes typical Roifman syndrome. NPJ Genom Med 2017; 10(2): 23. DOI: 10.1038/s41525–017–0024–5

20. El Marabti E., Malek J., Younis I. Minor Intron Splicing from Basic Science to Disease. Int J Mol Sci 2021; 22(11): 6062. DOI: 10.3390/ijms22116062

21. Heremans J., Garcia-Perez J.E., Turro E., Schlenner S.M., Casteels I., Collin R. et al. National Institute for Health Research BioResource; Thys C., Van Geet C., Van Nieuwenhove E., Wouters C., Meyts I., Freson K. et al. Abnormal differentiation of B cells and megakaryocytes in patients with Roifman syndrome. J Allergy Clin Immunol 2018; 142(2): 630–646. DOI: 10.1016/j.jaci.2017.11.061